Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:39 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–61 of 61 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Treg Clear all

Conditions: High Risk Hematologic Malignancies
Interventions: stem cell transplant, Stem cell transplant; Biological · Procedure
Lead sponsor: University of Utah; Other
Eligibility: Up to 70 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Late Complication From Kidney Transplant
Interventions: Treg infusion; Biological
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 50 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Acute Lymphoblastic Leukemia, Burkitt Lymphoma, Natural Killer Cell Malignancies, Chronic Myelogenous Leukemia, Myelodysplastic Syndromes, Large-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone B-Cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia, Hodgkin Lymphoma, Multiple Myeloma, Acute Myelogenous Leukemia, Biphenotypic Leukemia, Undifferentiated Leukemia
Interventions: Infusion of Treg; Biological
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years to 75 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Bone Marrow Disease
Interventions: CK0801; Biological
Lead sponsor: Cellenkos, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 2
States / cities: Santa Monica, California • Houston, Texas

Conditions: Graft Versus Host Disease, Allogeneic Hematopoietic Cell Transplant Recipient
Interventions: Regulatory T Cells; Biological
Lead sponsor: Laura Johnston; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Dual-Energy Computed Tomography, Echocardiography, Fludarabine, Magnetic Resonance Imaging, Melphalan, Multigated Acquisition Scan, Partially Engineered T-regulatory Cell Donor Graft TRGFT-201, Tacrolimus, Thiotepa, Total Marrow and Lymphoid Irradiation; Procedure · Drug · Biological + 1 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 60 Years and older
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Duarte, California

Conditions: Liver Transplant Recipient, Living Donor (of the Respective Liver Transplant Recipient)
Interventions: darTregs, Acetaminophen, Diphenhydramine, Immunosuppression (IS) Withdrawal, Study Mandated Procedures; Biological · Drug · Procedure
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 3
States / cities: San Francisco, California • Chicago, Illinois • Rochester, Minnesota

Conditions: Non Infectious Uveitis
Interventions: TRX103; Biological
Lead sponsor: Quan Dong Nguyen; Other
Eligibility: 18 Years to 70 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Amyotrophic Lateral Sclerosis
Interventions: RAPA-501 Autologous T stem cells; Other
Lead sponsor: Rapa Therapeutics LLC; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 10
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Irvine, California + 7 more

Conditions: Progressive Multiple Sclerosis
Interventions: ABA-101; Biological
Lead sponsor: Abata Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Baltimore, Maryland • New Brunswick, New Jersey • Cleveland, Ohio

Conditions: Rheumatoid Arthritis (RA), Hidradenitis Suppurativa (HS)
Interventions: Long Term Safety Monitoring Procedures; Other
Lead sponsor: Sonoma Biotherapeutics, Inc.; Industry
Eligibility: 18 Years to 71 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2040
U.S. locations: 10
States / cities: San Francisco, California • Stanford, California • Aurora, Colorado + 5 more

Conditions: Hematologic Malignancies
Interventions: CliniMACS CD25 Reagent Device; Device
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Stem Cell Transplant Complications, Graft Vs Host Disease, Myeloid Leukemia, Acute, Myeloid Leukemia in Relapse (Disorder), Myelodysplastic Syndromes
Interventions: Radiation, Fludarabine, Thiotepa, Cyclophosphamide, Mesna, Treg-enriched donor cell, Unmodified donor T Cell, CD34+ Haplo Peripheral Blood Stem Cell, Melphalan; Radiation · Drug · Biological + 1 more
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Phase I/II Study of Treg/Tcon Addback to Partially Matched Related Donor Stem Cells With Myeloablative Conditioning and Post-transplant Cyclophosphamide for High Risk Hematologic Malignancies

Treg Adoptive Therapy for Subclinical Inflammation in Kidney Transplantation

Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies

A Clinical Trial of CK0801 (a New Drug) in Patients With Bone Marrow Failure Syndrome (BMF)

Phase 1 Infused Donor T Regulatory Cells in Steroid Dependent/Refractory Chronic GVHD

Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome

Donor Alloantigen Reactive Tregs (darTregs) for Calcineurin Inhibitor (CNI) Reduction

A Proof-of-concept Trial to EvaluAte the efficaCy and Safety Of Cell Therapy TRX103 in Patients With Active, Non-infectious Uveitis

RAPA-501 Therapy of ALS Expanded Access Protocol

ABA-101 in Participants With Progressive Multiple Sclerosis

A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic

Infusion of Donor Lymphocytes Depleted of CD25+ Regulatory T-cells in Patients With Relapsed Hematologic Malignancies

IS-free Treg HaploHCT